Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Dev Immunol. 2010;2010:517493. doi: 10.1155/2010/517493. Epub 2010 Nov 4.

Dendritic cell-based immunotherapy for prostate cancer.

Author information

1
Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstrasse 74, Dresden, Germany.

Abstract

Dendritic cells (DCs) are professional antigen-presenting cells (APCs), which display an extraordinary capacity to induce, sustain, and regulate T-cell responses providing the opportunity of DC-based cancer vaccination strategies. Thus, clinical trials enrolling prostate cancer patients were conducted, which were based on the administration of DCs loaded with tumor-associated antigens. These clinical trials revealed that DC-based immunotherapeutic strategies represent safe and feasible concepts for the induction of immunological and clinical responses in prostate cancer patients. In this context, the administration of the vaccine sipuleucel-T consisting of autologous peripheral blood mononuclear cells including APCs, which were pre-exposed in vitro to the fusion protein PA2024, resulted in a prolonged overall survival among patients with metastatic castration-resistant prostate cancer. In April 2010, sipuleucel-T was approved by the United States Food and Drug Administration for prostate cancer therapy.

PMID:
21076523
PMCID:
PMC2975068
DOI:
10.1155/2010/517493
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Support Center